Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 1, 1999, Pages 40-49

  Lalonde, Richard L ^a,b,c   Gaudreault, Jacques ^a,b   Karhu, David A ^a,b   Marriott, Thomas B ^a,b  

^a MDS Inc   (Canada)

^b NPS Pharmaceutical Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; R 568; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANILINE COMPOUNDS; CALCIUM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; OVARIECTOMY; PARATHYROID HORMONE; POSTMENOPAUSE; TIME FACTORS;

EID: 0032892011     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70120-7     Document Type: Article

References (19)

1. 1. Potts JT. Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JP, Kasper DL, et al, editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p. 2227-47.
2. 2. Heath H. Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology. J Bone Miner Res 1991;6:S63-70.
3. 3. Kaplan EL, Salti G. Primary hyperparathyroidism in the 1990s: choice of surgical procedures for this disease. Ann Surg 1992;215:300-17.
4. 4. Daneyka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-8.
5. 5. Bragg P, Fischer DM, Shi J, Donati F, Meistelman C, Lau M, et al. Comparison of twitch depression of the adductor pollicis and the respiratory muscles: pharmacodynamic modeling without plasma concentrations. Anesthesiology 1994;80:310-9.
6. 6. Verotta D, Sheiner LB. Semiparametric analysis of nonsteady-state pharmacodynamic data. J Pharmacokinet Biopharm 1991;19:691-712.
7. 7. Sheiner LB, Ludden TM. Population pharmacokinetics/pharmacodynamics. Annu Rev Pharmacol Toxicol 1992; 32:185-209.
8. 8. Rodman JH, Silverstein MS. Comparison of two stage approach and first order methods for estimation of population parameters in an intensive pharmacokinetic study [abstract]. Clin Pharmacol Ther 1990;47:151.
9. 9. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters; II: biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981;9:635-51.
10. 10. Heat HIII. Primary hyperparathyroidism: recent advances in pathogenesis, diagnosis, and management. Adv Intern Med 1991;37:275-93.
11. 11. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.
12. 12. Sheiner LB, Beal SL, Sambol NC. Study design for dose-ranging. Clin Pharmacol Ther 1989;46:63-77.
13. 13. International Conference on Harmonization (ICH) Guideline for Industry. Dose-response information to support drug registration. Federal Register 1994;59:55972-6.
14. 14. Ratcliffe WA, Heath DA, Ryan M, Jones SR. Performance and diagnostic application of a two-site immunoradiometric assay for parathyrin in serum. Clin Chem 1989;35: 1957-61.
15. 15. Brasier AR, Wang CA, Nussbaum SR. Recovery of parathyroid hormone secretion after parathyroid adenomectomy. J Clin Endocrinol Metab 1988;66:495-500.
16. 16. Mayer GP, Habener JG, Potts JT. Parathyroid hormone secretion in vivo: demonstration of a calcium-independent, nonsuppressible component of secretion. J Clin Invest 1976;57:678-83.
17. 17. Khosla S, Ebeling PR, Firek AF, Burritt MM, Kao PC, Heath H. Calcium infusion suggests a "set-point" abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 1993;76:715-20.
18. 18. Logue FC, Fraser WD, O'Reilly DSJ, Cameron DA, Kelly AJ, Beastall GH. The circadian rhythm of intact parathyroid hormone (1-84): temporal correlation with prolactin secretion in normal men. J Clin Endocrinol Metab 1990;71:1556-60.
19. 19. Markowitz ME, Arnaud S, Rosen JF, Thorpy M, Laximinarayan S. Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations. J Clin Endocrinol Metab 1988;67: 1068-73.